Double-edged sword. by unknown
e - 9
chemotherapy or HIV. Therefore, flight
attendants and others say that airplane
cabin air should be held to higher stan-
dards than workplaces.
Pressure from passengers may be a
major contributing factor in encouraging
airlines to increase fresh air. In the August
issue of Consumer Reports, airlines were
ranked according to levels of carbon diox-
ide in airplane cabins and criticized for the
low amounts offresh air. Consumer Reports
recommended that passengers choose air-
lines according to the amounts offresh air
they circulate. They also recommended
that the FAA set a comfort standard of
1,000 ppm.
Double-Edged Sword?
Although individuals with genetic disor-
ders and diseases such as cancer, AIDS,
diabetes, or Alzheimer's may view the
potential of gene therapy as just the
weapon they're looking for, other people
perceive the "slicing and dicing" ofgenetic
material as a potential double-edged
sword. Scientists are attempting to esti-
mate the real risks associated with gene
therapy.
Most current gene therapies use retro-
viral vectors to transfer a therapeutic gene
into the cells of a patient who lacks a nor-
mally functioning copy of the gene.
Retroviral vectors are made by deleting
portions ofa retroviral genome and replac-
ing the deleted viral genes with the thera-
peutic gene. The resulting vector integrates
a DNA copy ofits genome, containing the
therapeutic gene, into the genome of a
host cell, but because of the missing viral
genes the vector cannot be replicated like a
normal retrovirus.
Typically, bone marrow cells are
removed and exposed to the vector in cul-
ture. The cells containing the therapeutic
gene are then infused back into the
patient. The fear is that the vector may
integrate its DNA copy near a gene
involved in regulation ofgrowth or devel-
opment of the cell and interfere with the
normal regulatory processes, causing the
cell to become cancerous. Although, says
toxicologist Richard Irwin of NIEHS,
"there is absolutely a finite probability
that it will occur," the risk of insertional
mutagenesis is believed to be very low.
The difficulty comes in trying to deter-
mine exactly what "very low" means in
terms of absolute risk to humans from
gene therapy.
Scientists are concerned about other
potential side effects ofthe process ofgene
therapy. First, it is not currently possible to
target a vector carrying a therapeutic gene
to a specific cell population. Expression of
the gene in nontargeted cells may interfere
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Cut and paste. Retroviral vectors are made by transferring a modified retrovirus into a packaging cell
which produces the desired protein in a target cell.
with regulation of cell processes or meta-
bolic pathways. Second, the transduced
cells may contain a selective growth advan-
tage, enabling their progeny to predomi-
nate in the host. When such cells are intro-
duced into a patient during gene therapy,
they represent a population carrying a
"first hit" insertional event that may put
the patient at increased risk for additional
mutational events leading potentially to
tumor formation. Third, retroviral vector
preparations may be contaminated by viri-
ons containing packaging cell RNA. In
theory, this RNA could be reverse-tran-
scribed, integrate in the genome of the
recipient cells, and express a product that
could disrupt normal cell functioning.
The risk posed by insertional mutagen-
esis is a particular concern for extending
gene therapy to the treatment of condi-
tions such as diabetes or hemophilia where
substantial numbers of people would be
candidates for the therapy and might be
treated early in their lives. A population of
cells carrying a first hit insertional event
would put such people at an increased risk
throughout the remainder oftheir lives.
As gene therapies are expanded for the
treatment ofmore diseases, the sheer num-
bers ofpeople involved makes it more like-
ly that even a relatively infrequent event
may result in an unacceptably high risk.
Irwin and his colleagues at the NIEHS are
developing studies to attempt to evaluate
the extent of this risk. In these studies,
researchers will expose mice and rats to
retroviral vectors in a number of ways.
These vectors contain marker genes which
allow the researchers to determine the
most effective method ofintegration ofthe
vector into the new cell genome. The ani-
mals are allowed to live out their life spans,
and researchers then examine them to see
if they developed tumors, and if so, if the
tumors contained DNA from the retroviral
vector. The information from these studies
will be used to estimate gene therapy's risk
and may help regulators evaluate the safety
ofcutting edge technology.
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